CCR6 and primary cutaneous T-cell non-Hodgkin lymphoma: The pan-HDACIs, vorinostat, and panobinostat, had been shown to reduce CTCL metastasis by targeting miR-150 and/or CCR6, which were important therapeutic targets for advanced CTCL with metastatic potential [41].